Divi's Laboratories — Q2 FY24
Divis Laboratories reported Q2 FY24 consolidated PAT of INR 348 crore on total income of INR 1,995 crore, with export share at 87%.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY24
MRI contrast media validation by end of FY24
Validation for some MRI contrast media products is expected to be completed by the end of the current financial year, enabling customer sampling.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1